For the quarter ended September 2026, Danaher (DHR) reported revenue of $6.55 billion, up 8.3% over the same period last year. EPS came in at $2.11, compared to $1.89 in the year-ago quarter.
The reported revenue represents a surprise of +0.1% over the Zacks Consensus Estimate of $6.55 billion. With the consensus EPS estimate being $1.92, the EPS surprise was +9.9%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Danaher performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Total Growth - Organic sales (Core): 3% compared to the 2.5% average estimate based on four analysts. Total Sales- Diagnostics: $2.88 billion versus the four-analyst average estimate of $2.83 billion. The reported number represents a year-over-year change of +17%. Total Sales- Life Sciences: $1.87 billion versus the four-analyst average estimate of $1.84 billion. The reported number represents a year-over-year change of +4.1%. Total Sales- Biotechnology: $1.81 billion versus $1.87 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +0.5% change. Operating profit- Life Sciences: $259 million versus the three-analyst average estimate of $255.41 million. Operating profit- Biotechnology: $477 million versus the three-analyst average estimate of $483.6 million. Operating profit- Other: $-105 million versus $-90.5 million estimated by three analysts on average. Operating profit- Diagnostics: $614 million versus the three-analyst average estimate of $704.1 million.View all Key Company Metrics for Danaher here>>>
Shares of Danaher have returned +1.4% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Danaher Corporation (DHR): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).